必赢电子

 
 
Dexin Kong, Professor
发布人:药必赢电子-英文  发布时间:2019-12-05   浏览次数:228

 

Dexin Kong, Ph.D.

 

 

Dexin Kong, PhD

Professor

Chair

Department of Clinical Pharmacy

Tianjin Medical University

22 Qixiangtai Road

Tianjin 300070

Phone: +86-22-83336673

Email: kongdexin@tmu.edu.cn

 

Education

Bachelor Shandong University, Jinan, China, 1991

Master    Shandong University, Jinan, China, 1994

Ph.D.  Osaka University, Osaka, Japan, 2005

 

Professional Experience

2010-            Professor, Department of Clinical Pharmacy, Tianjin Medical University, Tianjin, China

2006-2010   Senior scientist, Department of Molecular Pharmacology, JFCR, Tokyo, Japan

2005-2006   Research associate, School of Pharmacy, CUHK, Hong Kong SAR, China

1996-2000    Instructor, School of Life Sciences, Shandong University, Jinan, China

1994-1996   Assistant professor, School of Life Sciences, Shandong University, Jinan, China

Honors

1. 2013.05, Bridge fellowship, JSPS 

2. 2012.09, Awarded the title of Distinguished Professor of Tianjin

3. 2012.01, Invitation fellowship (short term), JSPS

 

Professional Service

 

Editorial Board

Journal of Cancer

Biochemistry & Pharmacology

E-journal of Chemistry

OA Cancer

 

Reviewer for:

International Journal of Cancer 

European Journal of Pharmacology

Current Medicinal Chemistry

Oncotarget 

Biomedicine and Pharmcotherapy

International Journal of Biological Sciences

Molecules

Phytochemistry letters

International Journal of Nanomedicine

Bioscience Reports

Food and Function

Academic conference chair

Chemotherapeutic Drug Discovery: Cancer Pharmacology Research Conference (New York, 2017)

 

Membership of Academic Society

American Association for Cancer Research (AACR)

Japanese Cancer Association (JCA)

Chinese Pharmacological Society (CPS)

 

Invited lectures

1. 69th annual meeting of Japanese Cancer Conference, September 2010, Osaka, Japan

2. 68th annual meeting of Japanese Cancer Conference, October, 2009, Yokohama, Japan

 

Books

Chemotherapy-Sensitizing Agents for Cancer (English), Editorial Board, 2017, in press. Elsevier.

 

Publication (selected)

1) Peng X, Zhou C, Hou X, Liu Y, Wang Z, Peng X, Zhang, Wang R, Kong D*. Molecular characterization and bioactivity evaluation of two novel bombinin peptides from the skin secretion of Oriental fire-bellied toad, Bombina orientalis. 2017, in press, doi: 10.1007/s00726-017-2509-z.

2) Zhou C, Wang Z, Peng X, Liu Y, Lin Y, Zhang Z, Qiu Y, Jin M, Wang R, Kong D*. Discovery of two Bombinin peptides with antimicrobial and anticancer activities from the skin secretion of Oriental Firebellied toad, Bombina orientalis. Chemical Biology & Drug Design, 2017, in press, doi: 10.1111/cbdd.13055.

3) Chen Y, Ji N, Pan S, Zhang Z, Wang R, Qiu Y, Jin M, Kong D*. Roburic Acid Suppresses NO and IL-6 Production via Targeting NF-κB and MAPK Pathway in RAW264.7 Cells. Inflammation, 2017, 40(6):1959-1966.

4) Chen X, Ji N, Qin N, Tang SA, Wang R, Qiu Y, Duan H, Kong D, Jin M. 4.1,6-O,O-Diacetylbritannilactone Inhibits Eotaxin-1 and ALOX15 Expression Through Inactivation of STAT6 in A549 Cells. Inflammation, 2017, 40(6):1967-1974.

5) Jin M, Kim S, Qin N, Chen X, Ji N, Tang SA, Kong D, Lee E, Duan H. 1,3.1,6-O,O-Diacetylbritannilactone suppresses activation of mast cell and airway hyper-responsiveness. Immunopharmacol Immunotoxicol, 2017, 39(4):173-179.

6) Zhou Q, Chen Y, Zhang L, Zhong Y, Zhang Z, Wang R, Jin M, Gong M, Qiu Y, Kong D*. Antiproliferative effect of ZSTK474 alone or in combination with chemotherapeutic drugs on HL60 and HL60/ADR cells. Oncotarget, 2017, 8(24):39064-39076.

7) Chen Y, Zhou Q, Zhang L, Zhong Y, Fan G, Zhang Z, Wang R, Jin M, Qiu Y, Kong D*. Stellettin B induces apoptosis in human chronic myeloid leukemia cells via targeting PI3K and Stat5. Oncotarget, 2017, 8(17): 28906-28921.

8) Wang R, Zhang Q , Peng X, Zhou C, Zhong Y, Chen X, Qiu Y, Jin M, Gong M, Kong D*. Stellettin B induces G1 arrest, apoptosis and autophagy in human Non-small cell lung cancer A549 Cells via blocking PI3K/Akt/mTOR pathway. Sci Rep, 2016,6: 27071.

9) Wang Y, Liu J, Qiu Y, Jin M, Chen X, Fan G, Wang R, Kong D*. ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells. Oncotarget, 2016, 7 (15): 19897-19909.

10) Huang C, Yi X, Kong D, Chen L, Gong M. Controlled release strategy of paclitaxel by conjugating to matrix metalloproteinases-2 sensitive peptide. Oncotarget. 2016, 7(32): 52230-52238.

11) Chen Y, Zhou Q, Zhang L, Wang R, Jin M, Qiu Y, Kong D*. Idelalisib induces G1 arrest and apoptosis in chronic myeloid leukemia K562 cells. Oncol Rep. 2016, 2016, 36: 3543-3650.

12) Wang P, He Y, Li D, Han R, Liu G, Kong D, Hao J. Class I PI3K inhibitor ZSTK474 mediates a shift in microglial/macrophage phenotype and inhibits inflammatory response in mice with cerebral ischemia/reperfusion injury. J Neuroinflammation. 2016, 13(1):192.

13) Zhao W, Qiu Y, Kong D*. Class I phosphatidylinositol 3-kinase inhibitors for cancer therapy. Acta Pharmaceutica Sinica B, 2016, 7(1):27-37.

14) Zhou Q, Chen Y, Chen X, Zhao W, Zhong Y, Wang R, Jin M, Qiu Y, Kong D*. In Vitro Antileukemia Activity of ZSTK474 on K562 and Multidrug Resistant K562/A02 Cells. Int J Biol Sci. 2016, 12(6): 631-8.

15) Xu J, Gao C, Zhang F, Ma X, Peng X, Zhang R, Kong D, Simard AR, Hao J. Differentially expressed lncRNAs and mRNAs identified by microarray analysis in GBS patients vs healthy controls. Sci Rep, 2016,6: 21819.

16) Li Y, Wang Y, Wei Q, Zheng X, Tang L, Kong D, Gong M*. Variant fatty acid-like molecules Conjugation, novel approaches for extending the stability of therapeutic peptides. Sci Rep, 2015; 5:18039.

17) Zhang F, Gao C, Ma X, Peng X, Zhang R, Kong D, Simard AR, Hao J*. Expression Profile of Long Noncoding RNAs in Peripheral Blood Mononuclear Cells from Multiple Sclerosis Patients. CNS Neurosci Ther, 2016, (4):298-305

18) Chen X, Xu H, Li B, Wang F, Chen X, Kong D, Lin X*. Preparation and Antitumor Activity of CS5931, A Novel Polypeptide from Sea Squirt Ciona Savignyi. Mar Drugs, 2016, 14: pii: E47.

19) Tang SA, Zhou Q, Guo W, Qiu Y, Wang R, Jin M, Zhang W, Li K, Yamori T, Dan S, Kong D*. In vitro Antitumor Activity of Stellettin B, a Triterpene from Marine Sponge Jaspis stellifera, on Human Glioblastoma Cancer SF295 Cells. Mar Drugs. 2014, 12: 4200-4213.

20) Chen X, Tang SA, Lee E, Qiu Y, Wang R, Duan HQ, Dan S, Jin M, Kong D*. IVSE, isolated from Inula japonica,suppresses LPS-induced NO production via NF-κB and MAPK inactivation in RAW264.7 cells. Life Sci, 2015; 124:8-15.

21) Wang X, Tang SA, Wang R, Qiu Y, Jin M, Kong D*. Inhibitory effects of JEUD-38, a new sesquiterpene lactone from Inula Japonica Thunb, on LPS-induced iNOS expression in RAW264.7 cells. Inflammation, 2015; 38(3):941-8.

22) Kong D*, Yamori T, Yamazaki K, Dan S*. In vitro multifaceted activities of a specific group of novel phosphatidylinositol 3-kinase inhibitors on hotspot mutant PIK3CA. Invest New Drugs, 2014, 32: 1134-1143.

23) Jin M, Zhou Q, Lee E, Dan S, Duan HQ, Kong D*. AS252424, a PI3K  Inhibitor, Downregulates Inflammatory Responsiveness in Mouse Bone Marrow-Derived Mast Cells. Inflammation, 2014, 37 (4): 1254-1260.

24Zhao W, Guo W, Zhou Q, Ma S, Wang R, Qiu Y, Jin M, Duan HQ, Kong D*. In Vitro Antimetastatic Effect of Phosphatidylinositol 3-Kinase Inhibitor ZSTK474 on Prostate Cancer PC3 Cells. Int. J. Mol. Sci. 2013, 14, 13577-13591.

25) Kong D, Yamori T*. JFCR39, a panel of 39 human cancer cell lines, and its application in the discovery and development of anticancer drugs. Bioorg. Med. Chem. 2012, 20 (6): 1947-1951.

26) Kong D, Dan S, Yamazaki K, Yamori T*. Inhibition profiles of phosphatidylinositol 3-kinase inhibitors against PI3K superfamily and human cancer cell line panel JFCR39. Eur. J. Cancer. 2010, 46 (6): 1111-1121.

27) Kong D, Okamura M, Yoshimi H, Yamori T*. Anti-angiogenic effect of a novel phosphatidylinositol 3-kinase inhibitor, ZSTK474. Eur. J. Cancer. 2009, 45 (3): 857-865. cover paper.

28) Jin M, Zhao W, Zhang Y, Kobayashi M, Duan H, Kong D*. Antiproliferative Effect of Aaptamine on Human Chronic Myeloid Leukemia K562 cells. Int. J. Mol. Sci. 2011, 12 (11): 7352-7359.

29) Kong D*, Zhang Y, Yamori T, Duan H, Jin M. Inhibitory Activity of Flavonoids against Class I Phosphatidylinositol 3-Kinase Isoforms. Molecules. 2011, 16 (6): 5159-67.

30) Kong D*, Yamori T, Kobayashi M, Duan H. Antiproliferative and antiangiogenic activities of Smenospongine, a marine sponge Sesquiterpene Aminoquinone. Mar. Drugs. 2011, 9 (2): 154-161.

31) Kong D, Yamori T*. Advances in development of Phosphatidylinositol 3-kinase inhibitors. Curr. Med. Chem. 2009, 16 (22): 2839-2854.

32) Kong D, Aoki S, Sowa Y, Sakai T, Kobayashi M*. Smenospongine, a sesquiterpene aminoquinone from a marine sponge, induces G1 arrest or apoptosis in different leukemia cells. Mar. Drugs 2008, 6 (3): 480-488.

33) Kong D, Yamori T*. Phosphatidylinositol 3-kinase inhibitors: promising drug candidates for cancer therapy. Cancer Sci. 2008, 99 (9): 1734-1740.

34) Kong D, Yamori T*. ZSTK474 is an ATP-competitive inhibitor of class I PI3 kinase isoforms. Cancer Sci. 2007, 98 (10): 1638-1642.

35) Kong D*. PI3K inhibitors: novel molecular-targeted drug candidates for cancer therapy. Biochem. Pharmacol. 2012, 1 (6): e126.

36) Kong D, Yamazaki K, Yamori T*. Discovery of phosphatidylinositol 3-kinase inhibitory compounds from the SCADS library. Biol. Pharm. Bull. 2010, 33 (9): 1600-1604.

37) Kong D, Okamura M, Yoshimi H, Yamori T*. Anti-angiogenic activity of a novel PI3K inhibitor, ZSTK474. EJC Suppl. 2008, 6 (12): 71.

38) Kong D, Yamori T*. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified by JFCR39 drug discovery system. Acta Pharmacol. Sin. 2010, 31 (9): 1189-1197.

39) Kong D, Yaguchi S, Yamori T*. Effect of ZSTK474, a Novel Phosphatidylinositol 3-kinase Inhibitor, on DNA-Dependent Protein Kinase. Biol. Pharm. Bull; 2009, 32 (2): 297-300.

40) Tang SA, Zhu H, Qin N, Zhou JY, Lee E, Kong DX, Jin MH, Duan HQ. Anti-inflammatory terpenes from flowers of Inula japonica. Planta Med. 2014, 80(7):583-9.

41) Ma Y, Jin YY, Wang YL, Wang RL, Lu XH, Kong DX, Xu WR.The discovery of a novel and selective inhibitor of PTP1B over TCPTP: 3D QSAR pharmacophore modeling, virtual screening, synthesis, and biological evaluation. Chem Biol Drug Des. 2014, 83(6):697-709.

42) Duan YQ, Ma Y, Wang XJ, Jin YY, Wang RL, Dong WL, Xu WR, Kong DX, Wang SQ. Design potential selective inhibitors for treating cancer by targeting the Src homology 2 (SH2) domain-containing phosphatase 2 (Shp2) with core hopping approach. Protein Pept Lett. 2014, 21(6):556-63.

43Qiu Y, Lee KS, Choo YM, Kong D, Yoon HJ, Jin BR*. Molecular cloning and antifibrinolytic activity of a serine protease inhibitor from bumblebee (Bombus terrestris) venom. Toxicon, 2013, 63C: 1-6.

44) Zhai, HY, Zhao C, Zhang N, Jin MN, Tang SA, Qin N, Kong DX, Duan HQ*. Alkaloids fromPachysandra terminalisInhibit Breast Cancer Invasion and Have Potential for Development As Antimetastasis Therapeutic Agents. J. Nat. Prod. 2012, 75, 1305-1311.

45) Sugita H, Dan S, Kong D, Tomida A, Yamori T*. A new evaluation method for quantifying PI3K activity. Biochem. Biophys. Res. Commun. 2008, 377 (3): 941-945.

46) Aoki S, Kong D, Suna H, Sowa Y, Sakai T, Setiawan A, Kobayashi M. Aaptamine, a spongean alkaloid, activates p21 promoter in a p53-independent manner. Biochem. Biophys. Res. Commun. 2006, 342 (1): 101-106.

47) Aoki S, Kong D, Matsui K, Kobayashi M. Erythroid differentiation in K562 chronic myelogenous cells induced by crambescidin 800, a pentacyclic guanidine alkaloid. Anticancer Res. 2004, 24(4):2325-2330.

48) Aoki S, Kong D, Matsui K, Kobayashi M. Sesquiterpene aminoquinones, from a marine sponge, induce erythroid differentiation in human chronic myelogenous leukemia, K562 cells. Chem. Pharm. Bull. 2004, 52(8):935-937.

49) Aoki S, Kong D, Matsui K, Kobayashi M. Smenospongine, a spongean sesquiterpene aminoquinone, induces erythroid differentiation in K562 cells. Anti-Cancer Drugs, 2004, 15(4):363-369.

                  

Grant

Ongoing:

1. Antitumor effect of STELB on glioblastoma and the related mechanism,NSFC, 2017.01-2020.12.

2. Establishment of an antitumor drug discovery system-KTC21. Major project of Tianjin for new drug development,2017.10-2020.09.

3. Anti-metastatic effect on prostate cancer by targeting PI3K isoforms with low molecular probes. NSFC, 2014.01-2017.12.

Completed:

1. Anti-metastatic effect of PI3K inhibitors on prostate cancer. Tianjin Natural Science Foundation. 2014.04-2016.03.


 
必赢电子【集团】股份有限公司